Search Results

You are looking at 31 - 40 of 1,411 items for :

  • "carcinoma" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

NCCN Guidelines Implementation in the Multidisciplinary Merkel Cell Carcinoma Program at the University of Michigan

Jennifer L. Schwartz, Sandra L. Wong, Scott A. McLean, James A. Hayman, Christopher D. Lao, Jeffrey H. Kozlow, Kelly M. Malloy, Carol R. Bradford, Marcus L. Frohm, Douglas R. Fullen, Lori Lowe, and Christopher K. Bichakjian

Merkel cell carcinoma (MCC), diagnosed primarily in the elderly white population, is an uncommon, clinically aggressive cutaneous malignancy with a high rate of local, regional, and distant recurrence. During the last 2 decades of the 20th century

Full access

Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy

David D. Chism

Urothelial carcinoma (UC) of the bladder is projected to account for 79,030 cases and 16,870 deaths in 2017 in the United States. 1 Median age at diagnosis is 73 years, with main risk factors including smoking, age, and male sex. Of the 70% of

Full access

Diagnostic and Therapeutic Delays in Patients With Hepatocellular Carcinoma

Ashwin Rao, Nicole E. Rich, Jorge A. Marrero, Adam C. Yopp, and Amit G. Singal

Background Hepatocellular carcinoma (HCC) mortality continues to increase in many countries, including the United States. 1 The 5-year survival for HCC remains <20%, in part related to failures in care delivery across the screening and

Full access

Medullary Thyroid Carcinoma: Management of Lymph Node Metastases

Jeffrey F. Moley

Medullary Thyroid Carcinoma Medullary thyroid carcinoma (MTC) comprises 3% to 9% of all thyroid cancers and arises from thyroid C cells. MTC has several distinctive features. First, MTC may be sporadic (75% of cases) or hereditary, occurring

Full access

Advanced Thyroid Carcinoma: Evolving Systemic Therapy Options

Presented by: Lori J. Wirth

potent efficacy and improved tolerability in RET- and NTRK ‐driven thyroid cancers, as well as in BRAF V600E–mutant anaplastic thyroid carcinomas (ATCs), and drugs that target these specific alterations have emerged as new standard-of-care therapies

Full access

Integration of Immunotherapy Into the Treatment of Advanced Urothelial Carcinoma

Pooja Ghatalia and Elizabeth R. Plimack

urothelial carcinoma. PD-L1 positivity is defined as a combined positive score of ≥10 for patients receiving pembrolizumab and immune cell 2/3 for patients receiving atezolizumab. In cisplatin-ineligible patients who are PD-L1–negative, chemotherapy with

Full access

Merkel Cell Carcinoma: A Population Analysis on Survival

Vishwajith Sridharan, Vinayak Muralidhar, Danielle N. Margalit, Roy B. Tishler, James A. DeCaprio, Manisha Thakuria, Guilherme Rabinowits, and Jonathan D. Schoenfeld

Background Merkel cell carcinoma (MCC) is a rare, cutaneous neuroendocrine cancer with an aggressive natural history. Epidemiologic studies indicate that MCC affects approximately 2.3 individuals per million, with incidence in the United

Full access

Radiotherapy in the Multidisciplinary Management of Merkel Cell Carcinoma

Michael D. Green and James A. Hayman

Merkel cell carcinoma (MCC) is a relatively rare cutaneous malignancy, predominantly diagnosed in elderly individuals (aged >70 years), that is increasing in incidence as the population ages. 1 Due to the rarity of this disease, there is a

Full access

PTCH1 Mutation in a Patient With Metastatic Undifferentiated Carcinoma With Clear Cell Change

Katy K. Tsai, Neharika Khurana, Timothy McCalmont, Adil Daud, Boris Bastian, and Iwei Yeh

studies are helpful in establishing the histogenesis of these tumors. Clear cell change has been described in epidermal tumors, including acanthoma, seborrheic keratosis, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC). BCC is the most common

Full access

Updates in the Systemic Therapy Options for Clear Cell and Non–Clear Cell Renal Cell Carcinoma

Presented by: Philippe E. Spiess, Peter A.S. Johnstone, and Eric Jonasch

Through the use of case studies, experts in renal cell carcinoma (RCC) explored the latest recommendations in the systemic treatment of patients with clear cell or non–clear cell disease at the NCCN 2023 Annual Conference. This discussion utilized